Intervention not reported
All‐cause and specific mortality · ethnic minority groups with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · ethnic minority groups with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
(a) Self‐efficacy and empowerment · ethnic minority groups with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
HbA1c [%] · ethnic minority groups with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Health economics: cost‐effectiveness [QALY] · ethnic minority groups with type 2 diabetes mellitus
1 finding from 1 review
BCVA: loss of 15 or more ETDRS letters · people with diabetic retinopathy
Laser photocoagulation showed no clear difference in loss of 15 or more letters BCVA compared with control (low certainty).
1 finding from 1 review
Visual acuity · people with diabetic retinopathy
1 finding from 1 review
Severe visual loss (BCVA < 6/60) · people with diabetic retinopathy
Laser photocoagulation probably leads to lower severe visual loss (BCVA < 6/60) compared with control (moderate certainty).
1 finding from 1 review
Quality of life · people with diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · people with diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of driving licence · people with diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cause mortality · people with cancer who have febrile neutropenia
beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Any nephrotoxicity ‐ Ag dosing regimen (Copy) · people with cancer who have febrile neutropenia
beta‐lactam monotherapy leads to lower any nephrotoxicity ‐ Ag dosing regimen (Copy) compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Clinical failure—same beta lactam Antibiotic modifications · people with cancer who have febrile neutropenia
beta‐lactam monotherapy probably leads to higher treatment failure ‐ same beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (moderate certainty).
1 finding from 1 review
Treatment failure ‐ different beta‐lactam · people with cancer who have febrile neutropenia
beta‐lactam monotherapy may leads to lower treatment failure ‐ different beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (low certainty).
1 finding from 1 review
Overall survival among all patients · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival among all patients compared with primary surgery (high certainty).
1 finding from 1 review
Presence of tumor‐free resection margin · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in presence of tumor‐free resection margin compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (T0 to T2 vs T3 to T4) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to higher tumor stage at resection (T0 to T2 vs T3 to T4) compared with primary surgery (moderate certainty).
1 finding from 1 review
Tumor stage at resection (N0 vs N+) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy may leads to higher tumor stage at resection (N0 vs N+) compared with primary surgery (low certainty).
1 finding from 1 review
Postoperative morbidity RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review